| Tradename: | Plegridy, Plegridy Pen |
| Dailymedid: | Peginterferon beta-1a |
| Pregnancy Au: | D |
| Pregnancy Au Comment: | [1] |
| Routes Of Administration: | Subcutaneous injection |
| Class: | Antineoplastic agent |
| Atc Prefix: | L03 |
| Atc Suffix: | AB13 |
| Legal Au: | S4 |
| Legal Au Comment: | [2] |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [3] |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Status: | Rx-only |
| Cas Number: | 1211327-92-2 |
| Drugbank: | DB09122 |
| Unii: | I8309403R0 |
| Kegg: | D10483 |
| Synonyms: | BIIB-017 |
| Iupac Name: | 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl) |
| Chemical Formula: | C913H1417N246O256PS7 [C2H4O]n |
| Molecular Weight: | 44000 |
| Molecular Weight Comment: | g·mol−1 |
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[4]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[5] [6]
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.